NEW YORK, NY--(Marketwired - September 30, 2016) - The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Misonix, Inc. ("Misonix") (NASDAQ: MSON) between November 5, 2015 and September 14, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Eastern District of New York. To get more information go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that defendants made false and/or misleading statements and/or failed to disclose that: (1) insufficiencies existed in Misonix's internal controls over financial reporting; and (2) consequently, Defendants' statements about Misonix's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
On September 14, 2016, Misonix revealed that the company would delay the filing of its Annual Report on Form 10-K for the year ending June 30, 2016 due to "deficiencies [that] existed in the Company's internal control over financial reporting at June 30, 2016." Misonix further announced that the company's Audit Committee was conducting an investigation related to the deficiencies. On this news, Misonix stock fell over 18%, to close at $5.00 per share on September 15, 2016.
If you suffered a loss in Misonix you have until November 18, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.